Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B
Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.
Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.